NHS Approves First Therapy to Delay Type 1 Diabetes Onset
In a groundbreaking move, the NHS will introduce teplizumab, a novel disease-modifying immunotherapy that can postpone the onset of symptomatic type 1 diabetes by almost three years. Following an evidence review by an independent NICE committee, England has become the first European nation to endorse this treatment through a health technology appraisal.
Also known as Tzield and manufactured by Sanofi, the therapy is officially recommended for adults and children aged eight and older who are currently in the early, pre-symptomatic stage (stage 2) of type 1 diabetes. This intervention provides invaluable time, giving patients a reprieve before they must manage the rigorous daily demands of stage 3 diabetes and allowing children to reach crucial developmental milestones uninterrupted.
Teplizumab functions by regulating the immune system, specifically by binding to the CD3 protein on immune cells, which slows the mistaken destruction of insulin-producing pancreatic cells. Administered via a daily intravenous drip over 14 consecutive days, the treatment was shown in the TN-10 clinical trial to delay the disease's progression by an average of 32 months. Once the two-week course is finished, no further doses are required, and the NHS has secured a confidential discounted price with the manufacturer to offer this single-course treatment.
Access to this preventative care will be available to eligible patients in England within 90 days of NICE's final guidance publication, and in Wales 60 days from June 23, 2026. Because stage 2 diabetes presents without symptoms, identifying eligible individuals relies on targeted testing. To support this, research initiatives like the ELSA and ELSD studies are actively expanding childhood screening across the UK, working alongside the NHS to build dedicated clinics and diagnostic pathways. It is anticipated that around 1,100 people may be eligible in the first year, eventually stabilizing to roughly 820 patients annually.
Health leaders and affected families have widely celebrated the announcement. Dr. Elizabeth Robertson of Diabetes UK called it a "landmark approval" that targets the root cause of the condition rather than simply treating it with insulin. Families involved in screening trials echoed this sentiment. Amy Norman, whose daughter's disease progression was slowed by the drug, emphasized how crucial this intervention is for preparing mentally and emotionally, noting, "Being forewarned is being forearmed – we know what is coming, but we're not scared".